General Information of Drug Therapeutic Target (DTT) (ID: TTY6EWA)

DTT Name Neuropeptide Y receptor type 5 (NPY5R)
Synonyms Y5 receptor; Neuropeptide Y receptor Y5; Neuropeptide Y (NPY) Y(5) receptor; NPYY5; NPY5R; NPY5-R; NPY-Y5 receptor
Gene Name NPY5R
DTT Type
Discontinued target
[1]
BioChemical Class
GPCR rhodopsin
UniProt ID
NPY5R_HUMAN
TTD ID
T20331
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MDLELDEYYNKTLATENNTAATRNSDFPVWDDYKSSVDDLQYFLIGLYTFVSLLGFMGNL
LILMALMKKRNQKTTVNFLIGNLAFSDILVVLFCSPFTLTSVLLDQWMFGKVMCHIMPFL
QCVSVLVSTLILISIAIVRYHMIKHPISNNLTANHGYFLIATVWTLGFAICSPLPVFHSL
VELQETFGSALLSSRYLCVESWPSDSYRIAFTISLLLVQYILPLVCLTVSHTSVCRSISC
GLSNKENRLEENEMINLTLHPSKKSGPQVKLSGSHKWSYSFIKKHRRRYSKKTACVLPAP
ERPSQENHSRILPENFGSVRSQLSSSSKFIPGVPTCFEIKPEENSDVHELRVKRSVTRIK
KRSRSVFYRLTILILVFAVSWMPLHLFHVVTDFNDNLISNRHFKLVYCICHLLGMMSCCL
NPILYGFLNNGIKADLVSLIHCLHM
Function
Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involved in feeding disorders.
KEGG Pathway
Neuroactive ligand-receptor interaction (hsa04080 )
Reactome Pathway
G alpha (i) signalling events (R-HSA-418594 )
Peptide ligand-binding receptors (R-HSA-375276 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [2]
Velneperit DMROSHN Obesity 5B81 Discontinued in Phase 2 [3]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [4]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [3]
RWJ-49815 DMUGZMO Fungal infection 1F29-1F2F Terminated [4]
------------------------------------------------------------------------------------
3 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [1]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [1]
NPY5RA-972 DMXUCSN Obesity 5B81 Preclinical [1]
------------------------------------------------------------------------------------
13 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2,4,4-triphenylimidazoline DMS8I1E Discovery agent N.A. Investigative [5]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [6]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH Discovery agent N.A. Investigative [7]
FMS586 DMQBTL3 Discovery agent N.A. Investigative [8]
FR-226928 DMBY3T5 Discovery agent N.A. Investigative [9]
FR-230481 DMKJQWR Discovery agent N.A. Investigative [9]
FR-233118 DMPD16N Discovery agent N.A. Investigative [9]
FR-73966 DMV0UM2 Discovery agent N.A. Investigative [9]
JCF 109 DMYF7AE Discovery agent N.A. Investigative [10]
L-152,804 DMVGX7Z Discovery agent N.A. Investigative [11]
LU-AA33810 DM34AYV Major depressive disorder 6A70.3 Investigative [12]
S-19528 DM589XM Eating disorder 6B82 Investigative [4]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Major depressive disorder 6A20 Pre-frontal cortex 7.49E-01 1.19E-02 0.03
------------------------------------------------------------------------------------

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
3 Clinical pipeline report, company report or official report of Shionogi (2011).
4 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5 Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1670-4.
6 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
7 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.
8 Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin... J Pharmacol Exp Ther. 2006 May;317(2):562-70.
9 Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
10 Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol. 2003 Aug;139(7):1360-8.
11 L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun. 2000 May 27;272(1):169-73.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 308).